Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
TSHA
#1815
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+0.44%
Monthly Change
-4.43%
6 month change
+51.51%
Year Change
+177.91%
Previous Close
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volume
115
Markets
US Stock Market
Healthcare
TSHA
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
204.94 M
205 M
214.66 M
272.79 M
273.92 M
—
Valuation ratios
Enterprise value
254.25 M
215.62 M
181.79 M
317.4 M
598.37 M
1.31 B
Price to earnings ratio
5.91
-4.81
-4.09
-6.79
-9.91
-25.6
Price to sales ratio
35.12
51.93
49.49
77.07
140.37
318.86
Price to cash flow ratio
5.06
5.33
4.24
7.61
11.23
28.41
Price to book ratio
1.2
6.05
1.08
1.39
1.68
10.2
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.14
0.12
0.16
0.08
0.1
0.46
Return on equity %
0.29
0.26
0.39
0.11
0.15
0.91
Return on invested capital %
257.93
221.99
263.06
359.78
441.35
1 286.18
Gross margin %
100
100
100
100
—
—
Operating margin %
1 448.43
985.76
930.54
1 347.08
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 427.52
929.03
935.23
1 353.58
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.51
5.42
5.35
12.48
10.48
33.72
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0.02
0.01
0
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.24
0.27
0.31
0.12
0.16
0.86
Long term debt to total equity ratio
0.48
0.61
0.77
0.17
0.23
1.78
Per share metrics
Operating cash flow per share
0.08
0.07
0.08
0.07
0.07
0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.59
0.56
0.43
1.05
0.84
2.88
Net current asset value per share
0.6
0.57
0.45
1.06
0.85
2.93
Tangible book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Working capital per share
0.49
0.46
0.36
0.98
0.77
2.57
Book value per share
0.33
0.29
0.2
0.83
0.62
1.94
News
스티펠, 뉴로진(Neurogene) 주식에 ’매수’ 등급 재확인
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
테이샤, 렛 증후군 유전자 치료 임상시험 첫 환자 투약
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
테이샤 유전자 치료제 주식, 52주 최고치인 $5.98 기록
Taysha Gene Therapies stock hits 52-week high at $5.98
제퍼리스, 2026년 유망 바이오 6개 종목 선정
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
테이샤 유전자 치료제, Citizens "시장 수익률 상회" 등급 재확인
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock
테이샤 유전자 치료제, 주당 5.51달러로 52주 최고치 기록
Taysha Gene Therapies stock hits 52-week high at 5.51 USD